 |
인쇄하기
취소
|
Viromed, Eureka to conduct joint research over antibody cancer drug
ViroMed Co., a local biopharmaceutical company, says it has signed a memorandum of understanding with the US based Eureka Therapeutics Inc. to accelerate the development of antibody cancer drugs, such as Swiss Drug Giant Roche’s Herceptin.
The agreement will provide ViroMed with Eureka’s proprietary technology platform for the enhancement of ADCC activity in recombinant antibodies through Fc...
The agreement will provide ViroMed with Eureka’s proprietary technology platform for the enhancement of ADCC activity in recombinant antibodies through Fc...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.